Literature DB >> 25186922

Differences between rosuvastatin and atorvastatin in lipid-lowering action and effect on glucose metabolism in Japanese hypercholesterolemic patients with concurrent diabetes. Lipid-lowering with highly potent statins in hyperlipidemia with type 2 diabetes patients (LISTEN) study –.

Hisao Ogawa1, Kunihiko Matsui, Yoshihiko Saito, Seigo Sugiyama, Hideaki Jinnouchi, Masahiro Sugawara, Izuru Masuda, Hisao Mori, Masako Waki, Minoru Yoshiyama, Hirotaka Watada.   

Abstract

BACKGROUND: Little is known about the differences between standard-dose statins effects on glucose level and lipids in Japanese patients with diabetes mellitus (DM). METHODS AND
RESULTS: The 1,049 patients were randomly assigned to either the rosuvastatin group or atorvastatin group. There were no significant differences between the 2 groups in the effect on non-high-density lipoprotein cholesterol (non-HDL-C) and HbA1c at 12 months. However, physicians tended to switch to more intensive therapy for DM in the atorvastatin group.
CONCLUSIONS: Rosuvastatin 5 mg and atorvastatin 10 mg have a similar lowering effect on non-HDL-C, but might be different in terms of adverse effect on glucose levels.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25186922     DOI: 10.1253/circj.cj-14-0810

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  12 in total

1.  Do statins adversely affect the HbA1c of diabetic patients?

Authors:  W D Son; C L Teng
Journal:  Malays Fam Physician       Date:  2017-04-30

Review 2.  Risk and Benefits of Statins in Glucose Control Management of Type II Diabetes.

Authors:  Anthony Paulo Sunjaya; Angela Felicia Sunjaya; Samuel Halim; Frans Ferdinal
Journal:  Int J Angiol       Date:  2016-02-18

3.  Effect of Ezetimibe on LDL-C Lowering and Atherogenic Lipoprotein Profiles in Type 2 Diabetic Patients Poorly Controlled by Statins.

Authors:  Kentaro Sakamoto; Mitsunobu Kawamura; Takahide Kohro; Masao Omura; Takayuki Watanabe; Keiko Ashidate; Toshiyuki Horiuchi; Hidehiko Hara; Nobuo Sekine; Rina Chin; Motoyoshi Tsujino; Toru Hiyoshi; Motoki Tagami; Akira Tanaka; Yasumichi Mori; Takeshi Inazawa; Tsutomu Hirano; Tsutomu Yamazaki; Teruo Shiba
Journal:  PLoS One       Date:  2015-09-23       Impact factor: 3.240

Review 4.  Is Atorvastatin Associated with New Onset Diabetes or Deterioration of Glycemic Control? Systematic Review Using Data from 1.9 Million Patients.

Authors:  Angeliki M Angelidi; Emelina Stambolliu; Konstantina I Adamopoulou; Antonis A Kousoulis
Journal:  Int J Endocrinol       Date:  2018-10-22       Impact factor: 3.257

5.  Early efficacy and safety of statin therapy in Korean patients with hypercholesterolemia: Daegu and Gyeongbuk Statin Registry.

Authors:  Han Joon Bae; Yun-Kyeong Cho; Hyoung-Seob Park; Hyuck-Jun Yoon; Hyungseop Kim; Seongwook Han; Seung-Ho Hur; Yoon-Nyun Kim; Kwon-Bae Kim; Jae-Kean Ryu; Deug Young Nah; Chang-Wook Nam
Journal:  Korean J Intern Med       Date:  2019-08-19       Impact factor: 2.884

Review 6.  Potential Alteration of Statin-Related Pharmacological Features in Diabetes Mellitus.

Authors:  Habibeh Mashayekhi-Sardoo; Stephen L Atkin; Fabrizio Montecucco; Amirhossein Sahebkar
Journal:  Biomed Res Int       Date:  2021-03-26       Impact factor: 3.411

7.  Co-Administration of Vitamin E and Atorvastatin Improves Insulin Sensitivity and Peroxisome Proliferator-Activated Receptor-γ Expression in Type 2 Diabetic Patients: A Randomized Double-Blind Clinical Trial.

Authors:  Banafsheh Sadat Tabaei; Seyedeh Neda Mousavi; Aliasghar Rahimian; Hadi Rostamkhani; Ali Awsat Mellati; Maryam Jameshorani
Journal:  Iran J Med Sci       Date:  2022-03

8.  Effects of switching to low-dose rosuvastatin (5 mg/day) on glucose metabolism and lipid profiles in Japanese patients with type 2 diabetes and dyslipidemia: a single-arm, prospective, interventional trial.

Authors:  Akiko Kameda; Akinobu Nakamura; Yoshinobu Kondo; Mari Kimura; Yasuo Terauchi
Journal:  Diabetol Int       Date:  2017-07-05

9.  Impact of Lowering Low-Density Lipoprotein Cholesterol with Contemporary Lipid-Lowering Medicines on Cognitive Function: A Systematic Review and Meta-Analysis.

Authors:  Hangying Ying; Jiacheng Wang; Zhida Shen; Meihui Wang; Binquan Zhou
Journal:  Cardiovasc Drugs Ther       Date:  2020-08-08       Impact factor: 3.727

10.  Effect of high-potency statins on HbA1c in patients with or without diabetes mellitus.

Authors:  Nobuhiro Ooba; Shoutarou Tanaka; Yu Yasukawa; Nariyasu Yoshino; Hiroyuki Hayashi; Shinji Hidaka; Toshiichi Seki; Noriyasu Fukuoka
Journal:  J Pharm Health Care Sci       Date:  2016-03-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.